Skip to main
PSTX
PSTX logo

Poseida Therapeutics (PSTX) Stock Forecast & Price Target

Poseida Therapeutics (PSTX) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Poseida Therapeutics Inc. has demonstrated significant advancements in its cell therapy portfolio, highlighted by promising results from its P-BCMA-ALLO1 clinical trial, where a heavily pretreated patient achieved a complete response after treatment. The company is enhancing its in-house manufacturing capabilities and exploring innovative technologies such as AI-assisted donor screening and improved gene editing efficiency, which could lead to higher product yields and overall therapeutic effectiveness. Additionally, the potential partnership with Roche is poised to leverage their extensive R&D and commercialization expertise, thereby maximizing the clinical and commercial prospects of Poseida's pipeline.

Bears say

Poseida Therapeutics has faced a downgrade in its rating due to a reassessment of its financial outlook, with a significant reduction in the 12-month price target from $20 to $9. This adjustment reflects concerns regarding the company’s progress and viability in advancing its CAR-T pipeline, especially in the context of clinical results such as the dose-dependent depletion of primary human B cells observed in preclinical models. Overall, these developments raise questions about Poseida's competitive positioning and potential for commercialization in a challenging biopharmaceutical landscape.

Poseida Therapeutics (PSTX) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Poseida Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Poseida Therapeutics (PSTX) Forecast

Analysts have given Poseida Therapeutics (PSTX) a Buy based on their latest research and market trends.

According to 5 analysts, Poseida Therapeutics (PSTX) has a Buy consensus rating as of Jul 28, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Poseida Therapeutics (PSTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.